Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Hippel James	2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Financial Officer
(Last)          (First)          (Middle) 614 MCKINLEY PLACE N.E.	3. Date of Earliest Transaction (MM/DD/YYYY) 1/11/2021
(Street) MINNEAPOLIS, MN 55413 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/11/2021		M		10000	A	$106.59	19137	D
Common Stock	1/11/2021		S(1)		400	D	$328.6809 (2)	18737	D
Common Stock	1/11/2021		S(1)		400	D	$330.265 (3)	18337	D
Common Stock	1/11/2021		S(1)		700	D	$331.6094 (4)	17637	D
Common Stock	1/11/2021		S(1)		2501	D	$333.2328 (5)	15136	D
Common Stock	1/11/2021		S(1)		3990	D	$334.3907 (6)	11146	D
Common Stock	1/11/2021		S(1)		2009	D	$334.9842 (7)	9137	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$106.59	1/11/2021		M			10000	(9)	8/18/2023	Common Stock	10000	$0	49942	D
Stock Options (Right to Buy)	$125.05							(9)	8/9/2024	Common Stock	24460		24460	D
Stock Options (Right to Buy)	$125.05							(10)	8/9/2024	Common Stock	32613		32613	D
Restricted Stock Units	(8)							(11)	(11)	Common Stock	3383		3383	D
Stock Options (Right to Buy)	$177.32							(11)	8/8/2025	Common Stock	18066		18066	D
Stock Options (Right to Buy)	$177.32							(12)	8/8/2025	Common Stock	24089		24089	D
Restricted Stock Units	(8)							(13)	(13)	Common Stock	3938		3938	D
Stock Options (Right to Buy)	$190.41							(13)	8/7/2026	Common Stock	19936		19936	D
Stock Options (Right to Buy)	$190.41							(14)	8/7/2026	Common Stock	26581		26581	D
Restricted Stock Units	(8)							(15)	(15)	Common Stock	3219		3219	D
Stock Options (Right to Buy)	$267.87							(15)	8/5/2027	Common Stock	14360		14360	D
Stock Options (Right to Buy)	$267.87							(16)	8/5/2027	Common Stock	19147		19147	D
Stock Options (Right to Buy)	$267.87							(17)	8/5/2027	Common Stock	8325		8325	D
Stock Options (Right to Buy)	$267.87							(18)	8/5/2027	Common Stock	8325.0		8325.0	D

Explanation of Responses:
(1)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.46 to $329.38, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.06 to $330.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.06 to $332.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.79 to $333.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(6)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.79 to $334.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(7)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.81 to $335.61, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(8)	Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
(9)	Fully exercisable.
(10)	Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.
(11)	Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(12)	Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
(13)	Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(14)	Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
(15)	Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(16)	Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
(17)	Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
(18)	Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			Chief Financial Officer

Signatures
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.		1/13/2021
**Signature of Reporting Person		Date